Introduction: Following rapid spread of the SARS‐CoV‐2 and COVID-19 pandemic, concerns for patients with IBD who are on immunosuppressive medications, increased. There were various important questions in patient with the background of IBD. In this review article was discussed about significant question that whether patients with IBD are more susceptible to COVID-19. Another important question is how to manage IBD patients which on drugs such as corticosteroid, immunosuppression and immunomodulation during the current pandemic and whether immunosuppression affects the progress of COVID-19. Other question is about IBD patient that infected by SARS‐CoV‐2 and concern about continue or discontinue immunomodulator or immunosuppressor drugs. Method: We reviewed literature & expert opinion on IBD, SARS‐CoV‐2 and COVID‐19 and discussed about several important questions in IBD patients & COVID-19 pandemic Results: This review was shown IBD patients are not more susceptible to SARS‐CoV‐2 infection and current data supports only high dose corticosteroid (more than 20 mg) may be increased risk of COVID-19 infection. Although in acute respiratory syndrome high dose corticosteroid, are recommended. IBD medication (Anti TNF and thiopurine) should be used to prevent disease flare. If a patient with IBD infected by COVID‐19 and leads to severe disease and hospitalization, immune suppressing medications (Anti-TNF) and immunomodulator drugs (thiopurine) should be discontinued until infection resolution. JAK inhibitor such as tofacitinib can decrease the number of lymphocytes, therefore stopping this drug until resolution of infection may be reasonable.